Review
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Mar 15, 2022; 14(3): 587-606
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.587
Table 4 Common gastrointestinal manifestations with their clinical possibilities and recommendations for practice
Gut and liver manifestation
Possible reasons at diagnosis
Possible reasons during therapy
Recommendations
Jaundice Tumor infiltration and necrosis of hepatocytes; Obstruction of biliary system by enlarged lymph nodes; Transfusion related viral hepatitis; Consider possibility of HLH as atypical presentation of hemato-lymphoid malignancies; Sclerosing cholangitis in a case of LCHChemotherapy induced liver injury (e.g., 6-MP, Methotrexate); Reactivation of viral infections (e.g., HBV, HCV, CMV, EBV)Screen for HBV, HCV, HIV before starting chemotherapy; Safe transfusion practices; Exercise pharmacovigilance (chemotherapeutic drug dose modifications with underlying hepatic impairment, therapeutic drug monitoring-e.g., Methotrexate); Screen for genetic polymorphisms (e.g., TPMT, NUDT15 genotype for 6-MP)[104]; Abdominal imaging either CT angio or MRCP with MRI on clinical basis; Prioritize chemotherapy initiation for underlying malignancy over waiting for resolution of HLH with HLH treatment protocol[105]; Initiation of antivirals before chemotherapy for hepatitis B, hepatitis C infection as per standard guidelines[106,107]
Liver failurePeculiar presentation with T-ALL, AML, TAM of newborn; Overwhelming sepsis at baseline due to poor immune reservePeculiar toxicity with L-asparaginase, high dose methotrexate and anthracyclines in predisposed individuals; Viral hepatitis especially hepatitis B reactivationEarly steroid initiation at presentation for preventing further liver cell necrosis in a case of ALL; Considering chemotherapy for TAM; FFP, cryoprecipitate product transfusions for hemostasis; Screen for hepatotrophic viral markers and appropriate antiviral therapy
Visceral perforationAdvanced stage lymphomas causing gut obstruction; Typhlitis due to severe neutropenia (e.g., AML); Appendicitis as presentation (especially with ALL)Post chemotherapy initiation with high grade lymphomas of stomach or intestine; C. difficile infectionAbdominal girth, bowel sound monitoring stringently in suspect cases; Abdominal imaging by CECT enterography with oral positive contrast; Stool examination in colitis for C. difficile; Anticipatory surgical consultation in advanced lymphomas
Bowel obstructionHigh grade lymphomas causing intussusception; Extrinsic nodal compression of gutVinca alkaloid induced paralytic ileus during therapy; Septic ileus during periods of neutropeniaAbdominal imaging with CECT enterography; Adequate broad spectrum antibiotic cover; Surgical consultation for intussusception; Continuous gastric /bowel drainage above the level of obstruction
GI bleedMucosal bleed due to thrombocytopenia at presentation; GI lymphoma[77]Thrombocytopeniainduced mucosal bleeds; Drug induced coagulopathy (e.g., peg-asparaginase); Typhlitis; C. difficile colitisConservative management with blood products; Laparotomy only in uncontrolled bleed for surgical resection; In suspect cases of C.difficile colitis, stool for toxin assay, GDH and consider colonoscopy
Pancreatitis Rare as initial presentationDrug induced (Asparaginase preparations, cytarabine)Do not rechallenge with the same drug in case of AAP; Genetic testing could have a future role in predicting the risk of drug induced pancreatitis
Ascites High grade lymphomas at presentation; Peritoneal lymphomatosis; Chylous ascites in prolonged untreated Hodgkins lymphomas; Reported cases of secondary BCS due to Burkitts lymphoma; Pancreatic ascites in severe pancreatitisDrug induced liver failure (ex. Anthracyclines at toxic dose, L-asparaginase)Ascitic fluid for flow cytometry and malignant cytology can provide rapid diagnosis; MCT supplementation for chylous ascites; Octreotide and TPN for refractory chylous ascites; Lymphangiography if refractory chylous ascites